Context:

With uncertainty in North American trade, General Motors Canada Chief Jack Uppal argues that the Canada–United States–Mexico Agreement (CUSMA) is crucial for keeping the auto sector integrated and protected from tariffs and global competition. He notes tariff pressures are monitored but currently absorbed, while affordability and value across GM’s lineup remain the priority. The piece highlights GM’s strong Canadian performance in H1 2026, including a notable EV sales uptick, and suggests that despite shifting production southward, GM’s alignment with Canadian consumer priorities persists. Meanwhile, officials in Canada signal ongoing deliberations on how the annual CUSMA review will be structured, ahead of a potential decade-long process that could end without a path to extension. The outlook remains uncertain, with leaders hoping for a resolution as talks continue.

Dive Deeper:

• GM Canada president Jack Uppal frames CUSMA as a shield against global competition, arguing it strengthens the auto industry’s integration across Canada, the U.S. and Mexico.

• Uppal notes that tariffs have prompted close monitoring and price-management efforts, but GM has so far kept its go-to-market price points stable despite tariff noise.

• GM’s Canadian market share stood at 15.4% in the first half of 2026, with 148,640 vehicles sold, including more than 30% year-over-year growth in EV sales.

• Even in Alberta, where EV uptake is modest, GM’s EV sales grew by about 30%, underscoring a broader push toward electrification within the country.

• Uppal emphasizes customer value, affordability, and the need for more choices, tech, and connectivity to meet consumer demand and dampen external uncertainties.

• The U.S. stance on terminating or renewing CUSMA remains unsettled, with talk of an annual review and possible termination, set to be completed within a framework that could stretch to 10 years

• Canadian officials, including Trade Minister Dominic LeBlanc, say discussions on how the annual review will be conducted are ongoing, with no clear pathway outlined yet.